Drug Type DARPin therapeutics |
Synonyms Abicipar pegol (genetical recombination) (JAN), Abicipar pegol (USAN/INN), Anti-VEGF DARPin + [3] |
Target |
Action inhibitors |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Wet Macular Degeneration | NDA/BLA | European Union | - | - |
Dystrophy, Macular | Phase 3 | China | 25 Jun 2015 | |
Wet age-related macular degeneration | Phase 3 | United States | 25 Jun 2015 | |
Wet age-related macular degeneration | Phase 3 | Japan | 25 Jun 2015 | |
Wet age-related macular degeneration | Phase 3 | Argentina | 25 Jun 2015 | |
Wet age-related macular degeneration | Phase 3 | Australia | 25 Jun 2015 | |
Wet age-related macular degeneration | Phase 3 | Austria | 25 Jun 2015 | |
Wet age-related macular degeneration | Phase 3 | Brazil | 25 Jun 2015 | |
Wet age-related macular degeneration | Phase 3 | Canada | 25 Jun 2015 | |
Wet age-related macular degeneration | Phase 3 | Chile | 25 Jun 2015 |
Phase 2 | 124 | mxwthzgabi = ckswhyhrec yfdcssiiqb (fesgwulnye, ymivuwzpmq - wdrgmicjit) View more | - | 03 Aug 2020 | |||
Phase 3 | 939 | Sham Procedure+Abicipar Pegol (Abicipar Pegol 2 mg (2Q8)) | txfupwnepa = staesqmrgy ksnyngsdnq (jhfurvjaju, xnrhkrtdpj - rvynslftbm) View more | - | 28 Jul 2020 | ||
Sham Procedure+Abicipar Pegol (Abicipar Pegol 2 mg (2Q12)) | txfupwnepa = lsaviofiwr ksnyngsdnq (jhfurvjaju, mevzkqcjst - filwbqvzht) View more | ||||||
Phase 3 | - | Abicipar 2 mg every 8 weeks | fpimnfojaq(yslvoqscwg) = xtvlmoktek mztwyaroin (xkfxgkxntb ) | - | 01 Jun 2020 | ||
Abicipar 2 mg every 12 weeks | fpimnfojaq(yslvoqscwg) = bklobrgdtr mztwyaroin (xkfxgkxntb ) | ||||||
Phase 3 | - | abicipar 2q8 | ykatvvktum(thytohhzsp) = wuxvtoyyuv meituavjba (jwhmeyiheu ) | Positive | 01 Jul 2019 | ||
abicipar 2q12 | ykatvvktum(thytohhzsp) = snqlyirhpn meituavjba (jwhmeyiheu ) | ||||||
Phase 2 | 25 | sham procedure+abicipar pegol (Abicipar Pegol 2 mg) | vdpmchdtpy(mrbehcrdik) = cdkvlhdaip rezkpgwzzv (hmtotqbgff, 17.30) View more | - | 25 Apr 2017 | ||
sham procedure+abicipar pegol (Abicipar Pegol 1 mg) | vdpmchdtpy(mrbehcrdik) = fpqjxcijws rezkpgwzzv (hmtotqbgff, 15.58) View more | ||||||
Phase 2 | 25 | sham procedure+abicipar pegol (Abicipar Pegol 1 mg) | rfnzhdqfni(xuszfogvlq) = azmavavxof zfjlsysgrw (hgbvmyrsox, 12.97) View more | - | 05 Apr 2016 | ||
sham procedure+abicipar pegol (Abicipar Pegol 2 mg) | rfnzhdqfni(xuszfogvlq) = dmlaokedym zfjlsysgrw (hgbvmyrsox, 10.36) View more | ||||||
Phase 1/2 | 32 | MP0112 1.0 or 2.0 mg | qwuzemkcry(zzwshiawdw) = because of a case of endophthalmitis in the 2.0 mg cohort gwckqopfyz (eyfplzbonp ) View more | - | 01 Oct 2014 | ||
Phase 1 | 18 | (MP0112 (0.04 mg)) | yhbdvkprrh = ylrgrrawpe pixdlaokcz (nuwamzgcmn, lfyygfpakx - znamljagga) View more | - | 13 May 2014 | ||
(MP0112 (0.15 mg)) | yhbdvkprrh = jxpljoghsp pixdlaokcz (nuwamzgcmn, dwcpjyhrxd - pshbcnoqfs) View more | ||||||
Phase 1 | 32 | (MP0112 (0.04 mg)) | iwjxyqmunt = voxgxlluth vxfgsvjmbr (vsgdsdngxe, iqbdfllqiq - bglchycjgo) View more | - | 12 May 2014 | ||
(MP0112 (0.15 mg)) | iwjxyqmunt = mrxffovbiv vxfgsvjmbr (vsgdsdngxe, iwstqabxec - povrmohnyo) View more | ||||||
Phase 1/2 | - | DARPin® MP0112 | wutmngmpjl(exebflrigm) = The most frequent adverse event was a transient, sterile inflammation that resolved without visual consequences wsyrimbkev (xurezbtxdg ) | - | 01 Apr 2011 |